<DOC>
	<DOCNO>NCT00704184</DOCNO>
	<brief_summary>A study evaluate effective different level Vaniprevir ( MK-7009 ) , administer Pegylated-Interferon ( Peg-IFN ) Ribavirin , achieve rapid viral response ( RVR ) i.e. , undetectable hepatitis C virus [ HCV ] viral ribonucleic acid [ RNA ] Week 4 participant chronic HCV infection . The primary hypothesis proportion participant one Vaniprevir treatment group achieve RVR would great proportion placebo participant achieve RVR Vaniprevir placebo co-administered Peg-IFN/Ribavirin .</brief_summary>
	<brief_title>Safety Efficacy Vaniprevir ( MK7009 ) Administered With Pegylated-Interferon Ribavirin ( MK-7009-007 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Patient chronic Genotype 1 Hepatitis C infection Subject previously treat HCV Has Human Immunodeficiency Virus ( HIV ) Has Hepatitis B Has history clinically significant medical condition may interfere study ( e.g. , stroke chronic seizure major neurological disorder ) contraindicate treatment pegIFN Ribavirin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>